G. Harty

发表

Cost Implications of Adapting The Investigation And Diagnosis Pathway of Infertilty Patients In A Uk Nhs Setting

S. Davies, A. Umranikar, T. Huggins, 2016 .

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work

M. Jofre-Bonet, G. Harty, J. Jarrett, 2018, Applied Health Economics and Health Policy.

Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods

G. Harty, N. Latimer, R. Hettle, 2019, Advances in Therapy.

Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis

G. Harty, A. Tafazzoli, Ameya A. Chavan, 2020, Advances in Therapy.

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

G. Harty, Schiffon Wong, A. Berardi, 2019, Current medical research and opinion.

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options

G. Harty, B. Donkers, M. Versteegh, 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

Cost Effectiveness Of Cetuximab In First Line Treatment Of Ras Wild-Type Metastatic Colorectal Cancer In The Uk: A Summary Of Economic Analyses Submitted To The National Institute For Health And Care Excellence (Nice).

G. Harty, A. Hnoosh, L. Sullivan, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Desirability and acceptability of a treatment-sequencing model in relapsing-remitting multiple sclerosis: A health technology assessment perspective

G. Harty, Schiffon Wong, M. Piena, 2020, International Journal of Technology Assessment in Health Care.

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

P. Vermersch, G. Harty, F. Dangond, 2020, Current medical research and opinion.

Use of rituximab in adults with relapsing–remitting multiple sclerosis: a systematic literature review

G. Harty, Schiffon Wong, M. K. Siddiqui, 2020, Current medical research and opinion.

Cost Effectiveness of Cetuximab in 1st-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium.

G. Harty, J. Jarrett, A. Hnoosh, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

G. Harty, Michael Tang, S. Budhia, 2019, European Neurological Review.

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis

G. Harty, R. Hettle, Schiffon Wong, 2018, Current medical research and opinion.

Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.

W. Brownlee, G. Harty, B. Hayward, 2023, Multiple sclerosis and related disorders.

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

G. Harty, R. Hettle, Schiffon Wong, 2018, Journal of medical economics.

An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach

G. Harty, Claire L. Simons, E. Fenwick, 2021, Advances in Therapy.

Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.

G. Harty, N. Latimer, R. Hettle, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

G. Harty, G. Hengstman, K. Schiffers, 2019, Applied Health Economics and Health Policy.

The value of treatment for infertility: A systematic literature review of willingness-to-pay thresholds and approaches for determining the cost effectiveness of fertility therapies.

G. Harty, E. Fenwick, S. Pandey, 2023, Best practice & research. Clinical obstetrics & gynaecology.

A Cost Utility Analysis Of Cetuximab For 1st-Line Treatment Of Ras Wild-Type Metastatic Colorectal Cancer: A Summary Of The Submission To All Wales Medicines Strategy Group (Awmsg).

G. Harty, A. Hnoosh, L. Sullivan, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Consequences Of Biomarker Analysis On The Cost-Effectiveness Of Cetuximab In Combination With Irinotecan Based Chemotherapy For First-Line Treatment Of Metastatic Colorectal Cancer. Stratified Medicine At Work?

M. Jofre-Bonet, G. Harty, J. Jarrett, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.

G. Harty, N. Latimer, R. Hettle, 2017, Value in Health.